Search Result

Results for "

PDCs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Peptide-Drug Conjugates (PDCs) (6) Anaplastic lymphoma kinase (ALK) (1) Apoptosis (3) Biochemical Assay Reagents (2) Caspase (1) Drug Isomer (1) Endogenous Metabolite (1) Ephrin Receptor (1) Epigenetic Reader Domain (2) Epoxide Hydrolase (1) FAK (1) Fc Receptor (FcR) (1) Folate Receptor (FR) (2) HSP (1) HSV (1) Human leukocyte immunoglobulin (Ig)-like receptors (LILR) (1) IFNAR (4) Influenza Virus (1) Interleukin Related (1) Nectin-4 (1) NF-κB (1) NKCC (1) PDHK (2) PDK-1 (1) Prostaglandin Receptor (2) PROTACs (5) PSMA (1) Radionuclide-Drug Conjugates (RDCs) (1) Reactive Oxygen Species (ROS) (2) SARS-CoV (2) Small Interfering RNA (siRNA) (3) Somatostatin Receptor (1) TNF Receptor (1) Toll-like Receptor (TLR) (5) Transketolase (1) Transmembrane Glycoprotein (1) TRP Channel (1)
By Research Areas:	Cancer (19) Endocrinology (1) Infection (3) Inflammation/Immunology (12) Metabolic Disease (2) Neurological Disease (2)
Oligonucleotides:	CpG ODNs (3) Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Oligonucleotides

Targets Recommended: Peptide-Drug Conjugates (PDCs)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-Y0445A

Sodium dichloroacetate Maximum Cited Publications 26 Publications Verification	PDK-1 NKCC PDHK Reactive Oxygen Species (ROS) Apoptosis	Cancer
Sodium dichloroacetate is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor. Sodium dichloroacetate also stimulates pyruvate dehydrogenase (PDH) activity and works as a Na ⁺-K ⁺-2Cl ⁻ cotransporter (NKCC) inhibitor. Sodium dichloroacetate prevents the phosphorylation of the E1α subunit of PDC, promoting the entry of pyruvate into the mitochondria for oxidative metabolism, reducing lactate production, and simultaneously increasing the production of reactive oxygen species (ROS). Sodium dichloroacetate inhibits tumor cell proliferation and induces apoptosis. Sodium dichloroacetate is promising for research of cancers .

HY-P99168

Anifrolumab 3 Publications Verification MDX-1333; MEDI-546	IFNAR	Inflammation/Immunology
Anifrolumab is a type I interferon (IFN) receptor antagonist, a human monoclonal antibody. Anifrolumab blocks the activity of type I interferon. Anifrolumab can be used in systemic lupus erythematosus (SLE) research .

HY-139567

Afimetoran 1 Publications Verification BMS-986256	Toll-like Receptor (TLR) NF-κB Apoptosis	Inflammation/Immunology
Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable TLR7/8 antagonist. Afimetoran (BMS-986256) can inhibit TLR7/8 activation of the NF-κB pathway and reverse TLR7 mediated resistance to steroid induced apoptosis in plasma cell like dendritic cells (pDCs). Afimetoran (BMS-986256) can be used for research on inflammation and autoimmune diseases (systemic lupus erythematosus) .

HY-12836A

IFN alpha-IFNAR-IN-1 hydrochloride 20+ Cited Publications	IFNAR	Inflammation/Immunology
IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC₅₀=2-8 μM) .

HY-132296

GSK215 2 Publications Verification	FAK PROTACs	Cancer
GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC₅₀ of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-150217

CpG ODN 10101 2 Publications Verification ODN 10101	Toll-like Receptor (TLR)	Infection Inflammation/Immunology
CpG ODN 10101 (ODN 10101; CPG 10101) is a selective agonist targeting TLR9, a synthetic oligodeoxynucleotide modified with phosphate thioester. CpG ODN 10101 activates B cells and plasmacytoid dendritic cells (pDCs), inducing the production of cytokines and chemokines such as interferon-IFN-α, interferon-inducible protein IP-10, and 2'5'-oligoadenylate synthase (2'5'-OAS), regulating innate immunity and promoting Th1 adaptive immune responses. CpG ODN 10101 also possesses antiviral properties and enhances vaccine immunogenicity, making it suitable as an immunomodulator and vaccine adjuvant for vaccine development in chronic hepatitis C and infectious diseases such as melioidosis, pertussis, and respiratory syncytial virus (RSV) .

HY-P11072

IRF5-CPP5	Toll-like Receptor (TLR) Interleukin Related TNF Receptor	Inflammation/Immunology
IRF5-CPP5 is a cytosolic peptide that selectively targeting human IRF5 wirh a K_d of 0.53 μM. IRF5-CPP5 disrupts IRF5 homodimerization and inhibits its nuclear translocation without altering IRF5 phosphorylation levels. IRF5-CPP5 inhibits proinflammatory cytokine (IL-6, IL-1β, TNF-α) production. IRF5-CPP5 can be used for the research of systemic lupus erythematosus .

HY-P10762

Ricorfotide vedotin CBP-1008; LDC 10B	Peptide-Drug Conjugates (PDCs) Folate Receptor (FR) TRP Channel	Cancer
Ricorfotide vedotin (CBP-1008) is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. Ricorfotide vedotin binds to FRα with high affinity and TRPV6 with low affinity. Ricorfotide vedotin has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .

HY-160719

2-octynoic acid-BSA	Peptide-Drug Conjugates (PDCs)	Inflammation/Immunology
NHS-activated 2-octynoic acid-BSA is an immunogen used to establish a mouse model of primary biliary cholangitis (PBC). When used in combination with Complete Freund's Adjuvant (HY-153808), NHS-activated 2-octynoic acid-BSA stimulates the body's immune system, which recognizes it as a foreign antigen and triggers an immune response against autologous biliary epithelial cells. This leads to the production of anti-PDC-E2 antibodies, causing bile duct damage and inflammation. NHS-activated 2-octynoic acid-BSA is promising for use in primary biliary cholangitis research .

HY-P10741

DOTA-EB-TATE	Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor	Cancer
DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-12836

IFN alpha-IFNAR-IN-1 20+ Cited Publications	IFNAR	Inflammation/Immunology
IFN alpha-IFNAR-IN-1 is a nonpeptidic, low-molecular-weight inhibitor of the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) (IC₅₀=2-8 μM) .

HY-P2796

Pyruvate decarboxylase PDC	Biochemical Assay Reagents	Metabolic Disease
Pyruvate decarboxylase (PDC) is an enzyme that catalyses the decarboxylation of pyruvic acid to acetaldehyde. Pyruvate decarboxylase catalyses the non-oxidative conversion of pyruvate (or other 2-oxo acids) to acetaldehyde and CO₂ .

HY-148511A

Vidutolimod sodium CMP-001 sodium	Toll-like Receptor (TLR)	Cancer
Vidutolimod sodium is a CpG-A oligodeoxynucleotide. Vidutolimod sodium is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFNα) release, leading to a cascade of anti-tumor immune effects.

HY-P99226

Daxdilimab MEDI7734; VIB7734	SARS-CoV Human leukocyte immunoglobulin (Ig)-like receptors (LILR)	Cancer
Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research .

HY-160231

ssRNA42 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
ssRNA42 (sodium) is a 20-mer phosphothioate protected single-stranded RNA oligonucleotide. ssRNA42 (sodium) derives from ssRNA40 by replacement of all G nucleotides with adenosine. ssRNA42 activated human PBMCs to secrete IFN-α, TNF-a, IL- 12p40, and IL-6, but ssRNA42 failed to stimulated murine pDCs and PBMCs.

HY-P10740

CBP-1018	Peptide-Drug Conjugates (PDCs) PSMA Folate Receptor (FR)	Cancer
CBP-1018 is a *PDC* (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E (HY-15162) to a dual-targeting ligand of FLOR1/PSMA (prostate-specific membrane antigen) via a linker (HY-78738). CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer .

HY-P4160

PDC31 THG113.31; ILGHXDYK	Prostaglandin Receptor	Endocrinology
PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca ²⁺-dependent large-conductance K ⁺-channel in human myometrial cells .

HY-128606

Thiamine diphosphate analog 1	Endogenous Metabolite Transketolase	Neurological Disease Metabolic Disease
Thiamine diphosphate analog 1 is an analog of thiamine diphosphate. Thiamine diphosphate is the active metabolite of vitamin B₁ in organisms. Thiamine diphosphate targets ThDP-dependent enzymes such as transketolase and pyruvate dehydrogenase complex, acting as an essential coenzyme to exert an activating effect. Thiamine diphosphate assists in catalytic reactions in free form and initiates the catalytic cycles of various glucose-metabolizing enzymes. Thiamine diphosphate serves as a diagnostic biomarker and protective factor for Alzheimer's disease. Thiamine diphosphate can be used in research related to metabolism and Alzheimer's disease .

HY-178489

BGC1614	Nectin-4	Cancer
BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an K_D of 3.859 × 10 ^-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .

HY-155393

PROTAC BRD4 Degrader-22	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-22 (Compd 44h) is a PROTAC-based BRD4 degrader, with a pDC₅₀ (MOLT4, 24 h) of 9.2 .

HY-179166

PROTAC sEH-degrader-4	PROTACs Epoxide Hydrolase	Inflammation/Immunology
PROTAC sEH-degrader-4 is a highly efficient PROTAC degrader that targets soluble epoxide hydrolase (sEH) (pDC₅₀ = 10.3). PROTAC sEH-degrader-4 can be used for research on inflammation-related diseases. Pink: sEH ligand (HY-179169); Blue: E3 ligase CRBN ligand (HY-179168); Black: Linker .

HY-P990276

Anti-Mouse CD317/BST2 Antibody (927)	Transmembrane Glycoprotein	Infection Inflammation/Immunology Cancer
Anti-Mouse CD317/BST2 Antibody (927) is a rat-derived IgG2b κ type antibody inhibitor, targeting to mouse CD317/BST2. Anti-Mouse CD317/BST2 Antibody (927) can deplete plasmacytoid dendritic cells (pDC). Anti-Mouse CD317/BST2 Antibody (927) can be used for the researches of cancer, infection, inflammation and immunology, such as head and neck squamous cell carcinoma (HNSCC), murine cytomegalovirus (MCMV) infection and asthma .

HY-156786

TLD-1433	Reactive Oxygen Species (ROS) Influenza Virus SARS-CoV HSV	Infection
TLD-1433 is the fourth-generation ruthenium (II) based photodynamic compound (PDC). TLD-1433 is activated by green light (525 ± 25 nm) and efficiently generates ROS to achieve pathogen inactivation. After photoinactivation, TLD-1433 significantly induces lipid peroxidation of the cell membrane, which can directly damage the integrity of the viral envelope. TLD-1433 has ID₅₀ for enveloped viruses (such as H1N1 influenza virus, coronavirus OC43, HSV-1, Zika virus) is as low as nanomolar level; for non-enveloped viruses (such as adenovirus Ad5, mammalian rotavirus MRV), a concentration of micro-molar level is required for inactivation. TLD-1433 has antigen retention property and can be used for the preparation of inactivated vaccines .

HY-170838

PDHK1-IN-1	PDHK	Cancer
PDHK1-IN-1 (compound 17) is a selective inhibitor of PDHK1 (IC₅₀=1.5 μM) with anticancer activity. PDHK1 negatively regulates the pyruvate dehydrogenase complex (PDC), limiting the tricarboxylic acid (TCA) cycle and oxidative phosphorylation. Overexpression of PDHK1 can shift the metabolism towards an increased glycolysis dependence (Warburg effect). PDHK1-IN-1 can inhibit the phosphorylation of the PDC E1α Ser232 recognition site of PDHK1 and the phosphorylation of Ser293 .

HY-174920

PROTAC BRD4 Degrader-34	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-34 (Compound MZ2) is a selective BRD4 PROTAC degrader (pDC₅₀ = 8.4). PROTAC BRD4 Degrader-34 can induce BD2 degradation mediated by VHL. PROTAC BRD4 Degrader-34 can be used for research on cancer. (Pink: BRD4-BD2 Ligand (HY-78695); Blue: VHL Ligand (HY-125845); Black: Linker (HY-130524)) .

HY-P11018

(123B9)2-L2-PTX	Peptide-Drug Conjugates (PDCs) Ephrin Receptor	Cancer
(123B9)2-L2-PTX is an EphA2-agonistic peptide-drug conjugate (PDC). (123B9)2-L2-PTX consists of a dimeric 123B9 (HY-P10579) and Paclitaxel (HY-B0015). (123B9)2-L2-PTX significantly reduces circulating tumor cells and inhibits lung tumor metastasis in breast-cancer-Metastasis mice model. (123B9)2-L2-PTX can be used for cancers research, such as melanomas and ovarian and breast cancers .

HY-RS23854

Pdc Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pdc Rat Pre-designed siRNA Set A contains three designed siRNAs for Pdc gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pdc Rat Pre-designed siRNA Set A Pdc Rat Pre-designed siRNA Set A

HY-RS10184

PDC Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
PDC Human Pre-designed siRNA Set A contains three designed siRNAs for PDC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

PDC Human Pre-designed siRNA Set A PDC Human Pre-designed siRNA Set A

HY-106195

L 377202	Peptide-Drug Conjugates (PDCs) Prostaglandin Receptor	Cancer
L 377202 is a peptide-drug conjugate (PDC). L 377202 consists of Doxorubicin (HY-15142A) and a prostate-specific antigen (PSA)-hydrolyzable peptide. L 377202 demonstrates strong inhibitory effects on PSA-secreting prostate cancer cells. L 377202 is promising for research of prostate cancer .

HY-P1094

AZ-10417808	Apoptosis Caspase	Inflammation/Immunology Cancer
AZ-10417808 is a selective caspase-3 inhibitor. AZ-10417808 blocks apoptosis signaling pathway by inhibiting caspase-3 activity. AZ-10417808 can be used to study the effect of nicotine on plasmacytoid dendritic cell migration .

HY-RS17399

Pdc Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Pdc Mouse Pre-designed siRNA Set A contains three designed siRNAs for Pdc gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Pdc Mouse Pre-designed siRNA Set A Pdc Mouse Pre-designed siRNA Set A

HY-182173

pdC-CE phosphoramidite
pdC-CE phosphoramidite is a phosphoramidite that can be used in the synthesis of oligonucleotides.

HY-138794B

XL177B (R)-XL177A	Drug Isomer	Cancer
XL177B is an inactive (R) enantiomer of XL177A (HY-138794). XL177B has no effect on CD86 or HLA-DR expression on pDCs. XL177B serves as a negative control. XL177B can be used in the research of multiple myeloma .

HY-W800833

Benzyl N-[2-(prop-2-enamido)ethyl]carbamate	Biochemical Assay Reagents	Others
Benzyl N-[2-(prop-2-enamido)ethyl]carbamate is a short aliphatic linker featuring a Cbz-protected amine and an acrylamide. Acrylamide is a Michael acceptor which is a good Michael acceptor which can be used in thiol-based bioconjugation or polymerization. Meanwhile, the Cbz protecting group can be removed using Pd-C hydrogenation to reveal a free amine that can participate in a wide variety of reactions such as couplings or reductive amination.

HY-183718

M4K3250	PROTACs Anaplastic lymphoma kinase (ALK)	Neurological Disease Cancer
M4K3250 is a selective ALK2 PROTAC degrader with a *pDC₅₀* of 7.9. M4K3250 induces the formation of a ternary complex between ALK2 and the E3 ubiquitin ligase CRBN, thereby causing ALK2 degradation and inhibiting ALK2 activity. M4K3250 exhibits cytotoxicity in glioblastoma cells. M4K3250 can be used in studies related to glioblastoma .

HY-183717

M4K3233		Cancer
M4K3233 is a selective ALK2 PROTAC degrader with a *pDC₅₀* of 7.3 and a pIC₅₀ of 6.6. M4K3233 recruits CRBN to form a ternary complex with ALK2, mediating ALK2 degradation via the proteasomal and lysosomal pathways. M4K3233 induces moderate downregulation of RIPK2 and significant downregulation of SIK3 in mammalian cells. M4K3233 is applicable to research related to glioblastoma .

HY-183866

MPD-1 Maleimide-KGDEVD-doxorubicin	HSP IFNAR	Cancer
MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 enhances CD8 ⁺ T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer .

Cat. No.	Product Name	Target	Research Area